Genomic Instability and Tumorigenesis are Long-Term Effects of Therapeutic CRISPR/Cas9 Genome Editing in Hereditary Tyrosinemia Type I

被引：0

作者：

Bissig, Karl-Dimiter ^{[1
]}

Furey, Nika ^{[1
]}

Chen, Tong ^{[1
]}

Kim, Hyunjae Ryan ^{[2
]}

Pankowicz, Francis ^{[2
]}

Barzi, Mercedes ^{[1
]}

Legras, Xavier ^{[1
]}

Martins, Celeste Santos ^{[2
]}

Elsea, Sarah ^{[3
]}

Hurley, Ayrea ^{[2
]}

Wheeler, David ^{[2
]}

Borowiak, Malgorzata ^{[2
]}

Bissig-Choisat, Beatrice ^{[1
]}

Lagor, William ^{[2
]}

Sumazin, Pavel ^{[2
]}

机构：

[1] Duke Univ, Durham, NC USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Baylor Coll Med, Houston, NC USA

来源：

MOLECULAR THERAPY | 2020年 / 28卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

961

引用

页码：419 / 420

页数：2

共 50 条

[1] CRISPR/Cas9 Gene Editing Increases the Risk of Tumorigenesis in Hereditary Tyrosinemia Type I
Chen, Tong
Barzi, Mercedes
Furey, Nika
Kim, Hyunjae R.
Pankowicz, Francis
Legras, Xavier
Elsea, Sara H.
Hurley, Ayrea M. S.
Wheeler, David A.
Borowiak, Malgorzata
Bissig-Choisat, Beatrice
Sumazin, Pavel
Bissig, Karl-Dimiter
MOLECULAR THERAPY, 2023, 31 (04) : 723 - 723
[2] Long-Term Consequences of CRISPR/Cas9 Gene Editing in a Mouse Model for Hereditary Tyrosinemia Type I
Pankowicz, Francis P.
Barzi, Mercedes
Legras, Xavier
Elsea, Sarah
Hurley, Ayrea E.
Bissig-Choisat, Beatrice
Borowiak, Malgorzata
Lagor, William R.
Sumazin, Pavel
Bissig, Karl-Dimiter
MOLECULAR THERAPY, 2019, 27 (04) : 240 - 240
[3] CRISPR/Cas9 gene therapy increases the risk of tumorigenesis in the mouse model of hereditary tyrosinemia type I
Chen, Tong
Barzi, Mercedes
Furey, Nika
Kim, Hyunjae R.
Pankowicz, Francis P.
Legras, Xavier
Elsea, Sara H.
Hurley, Ayrea E.
Yang, Diane
Wheeler, David A.
Borowiak, Malgorzata
Bissig-Choisat, Beatrice
Sumazin, Pavel
Bissig, Karl-Dimiter
JHEP REPORTS, 2025, 7 (04)
[4] Advances in therapeutic CRISPR/Cas9 genome editing
Schwank, G.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1053 - 1053
[5] Advances in therapeutic CRISPR/Cas9 genome editing
Savic, Natasa
Schwank, Gerald
TRANSLATIONAL RESEARCH, 2016, 168 : 15 - 21
[6] Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, Xiaojie
Wan, Tao
Xin, Huhu
Li, Da
Pan, Hongming
Wu, Jun
Ping, Yuan
JOURNAL OF GENE MEDICINE, 2019, 21 (07):
[7] Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9
Wang, Yanlin
Hao, Lei
Wang, Hongcai
Santostefano, Katherine
Thapa, Arjun
Cleary, John
Li, Hui
Guo, Xiuming
Terada, Naohiro
Ashizawa, Tetsuo
Xia, Guangbin
MOLECULAR THERAPY, 2018, 26 (11) : 2617 - 2630
[8] THERAPEUTIC GENOME EDITING FOR MYOTONIC DYSTROPHY TYPE 1 USING CRISPR/CAS9
Xia, G.
Wang, Y.
Hao, L.
Wang, H.
Santostefano, K.
Thapa, A.
Cleary, J.
Li, H.
Guo, X.
Terada, N.
Ashizawa, T.
MUSCLE & NERVE, 2018, 58 : S2 - S2
[9] CRISPR/Cas9 Genome Editing Therapy for Hereditary Pulmonary Alveolar Proteinosis
Shima, K.
Suzuki, T.
Ma, Y.
Mayhew, C.
Sallese, A.
Carey, B. C.
Arumugam, P.
Trapnell, B. C.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[10] Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders
Chen, Yan
Wen, Ruiting
Yang, Zhigang
Chen, Zhanghui
GENE THERAPY, 2022, 29 (05) : 207 - 216

← 1 2 3 4 5 →